Neonatal perturbation of neurotrophic signaling results in abnormal sensorimotor gating and social interaction in adults: Implication for epidermal growth factor in cognitive development

Molecular Psychiatry

Volumn 8, Issue 1, 2003, Pages 19-29

  Futamura, T ^a   Kakita, A ^a   Tohmi, M ^a   Sotoyama, H ^b   Takahashi, H ^a   Nawa, H ^a  

^a NIIGATA UNIVERSITY   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

Author keywords

EGF; HB EGF; PPI; Schizophrenia; Social interaction; TGF

Indexed keywords

CLOZAPINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AVOIDANCE BEHAVIOR; BEHAVIOR DISORDER; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; GLIA; HUMAN; HUMAN TISSUE; MESENCEPHALON; MOTOR ACTIVITY; NERVE CELL DIFFERENTIATION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SIGNAL TRANSDUCTION; SOCIAL INTERACTION; STARTLE REFLEX;

ANIMALS; ANIMALS, NEWBORN; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; BRAIN; BRAIN CHEMISTRY; COGNITION; EPIDERMAL GROWTH FACTOR; FEMALE; MOTOR ACTIVITY; MOTOR NEURONS; NEURONS, AFFERENT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SOCIAL BEHAVIOR; STARTLE REACTION;

EID: 0344951295     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001138     Document Type: Article

References (59)

1. Groenen LC, Nice EC, Burgess AW. Structure-function relationships for the EGF/TGF-family of mitogens. Growth Factors 1994; 11: 235-257.
2. Xian CJ, Zhou XF. Roles of transforming growth factor-alpha and related molecules in the nervous system. Mol Neurobiol 2000; 20: 157-183.
3. Brown KD. The epidermal growth factor/transforming growth factor-alpha family and their receptors. Eur J Gastroenterol Hepatol 1995; 7: 914-922.
4. Plata-Salaman CR. Epidermal growth factor and the nervous system. Peptides 1991; 12: 653-663.
5. Ferrari G, Toffano G, Skaper SD. Epidermal growth factor exerts neuronotrophic effects on dopaminergic and GABAergic CNS neurons: comparison with basic fibroblast growth factor. J Neurosci Res 1991; 30: 493-497.
6. Ishiyama J, Saito H, Abe K. Epidermal growth factor and basic fibroblast growth factor promote the generation of long-term potentiation in the dentate gyrus of anaesthetized rats. Neurosci Res 1991; 12: 403-411.
7. Morrison RS, Kornblum HI, Leslie FM, Bradshaw RA. Trophic stimulation of cultured neurons from neonatal rat brain by epidermal growth factor. Science 1987; 238: 72-75.
8. Adamson ED, Meek J. The ontogeny of epidermal growth factor receptors during mouse development. Dev Biol 1984; 103: 62-70.
9. Gomez-Pinilla F, Knauer DJ, Nieto-Sampedro M. Epidermal growth factor receptor immunoreactivity in rat brain. Development and cellular localization. Brain Res 1988; 438: 385-390.
10. Sibilia M, Steinbach JP, Stingl L, Aguzzi A, Wagner EF. A strain-independent postnatal neurodegeneration in mice lacking the EGF receptor. EMBO J 1998; 17: 719-731.
11. Blum M. A null mutation in TGF-alpha leads to a reduction in midbrain dopaminergic neurons in the substantia nigra. Nature Neurosci 1998; 1: 374-377.
12. Hilakivi-Clarke LA, Goldberg R. Effects of tryptophan and serotonin uptake inhibitors on behavior in male transgenic transforming growth factor alpha mice. Eur J Pharmacol 1993; 237: 101-108.
13. Hilakivi-Clarke LA, Corduban TD, Taira T, Hitri A, Deutsch S, Korpi ER et al. Alterations in brain monoamines and GABAA receptors in transgenic mice overexpressing TGF alpha. Pharmacol Biochem Behav 1995; 50: 593-600.
14. Prolo P, Licinio J. Cytokines in affective disorders and schizophrenia: new clinical and genetic findings. Mol Psychiatry 1999; 4: 109-111.
15. Weinberger DR. The biological basis of schizophrenia. J Clin Psychiatry Monogr 1997; 15: 4-6.
16. Tager-Flusberg H, Joseph R, Folstein S. Current directions in research on autism. Ment Retard Dev Disabil Res Rev 2001; 7: 21-29.
17. Nawa H, Takahashi M, Patterson PH. Cytokine and growth factor involvement in schizophrenia - support for the developmental model. Mol Psychiatry 2000; 5: 594-603.
18. Jankowsky JL, Patterson PH. Cytokine and growth factor involvement in long-term potentiation. Mol Cell Neurosci 1999; 14: 273-286.
19. Futamura T, Toyooka K, Iritani S, Niizato K, Nakamura R, Tsuchiya K et al. Abnormal expression of epidermal growth factor and its receptor in the forebrain and serum of schizophrenia patients. Mol Psychiatry 2002; 7: 000-000.
20. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci 1990; 13: 272-276.
21. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K et al. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacol (Berl) 1995; 120: 67-74.
22. Lijam N, Paylor R, McDonald MP, Crawley JN, Deng CX, Herrup K et al. Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. Cell 1997; 90: 895-905.
23. Jaber M, Jones S, Giros B, Caron MG. The dopamine transporter: a crucial component regulating dopamine transmission. Movement Disord 1997; 12: 629-633.
24. Mohn AR, Gainetdinov RR, Caron MG, Koller BH. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 1999; 98: 427-436.
25. Lipska BK, Jaskiw GE, Weinberger DR. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 1993; 9: 67-75.
26. Pulver AE. Search for schizophrenia susceptibility genes. Biol Psychiatry 2000; 47: 221-230.
27. Mowry BJ, Nancarrow DJ. Molecular genetics of schizophrenia. Clin Exp Pharmacol Physiol 2001; 28: 66-69.
28. Pedersen CB, Mortensen PB. Family history, place and season of birth as risk factors for schizophrenia in Denmark: a replication and reanalysis. Br J Psychiatry 2001; 179: 46-52.
29. Calamandrei G, Alleva E. Epidermal growth factor has both growth-promoting and growth-inhibiting effects on physical and neurobehavioral development of neonatal mice. Brain Res 1989; 477: 1-6.
30. Cartmell J, Salhoff CR, Perry KW, Monn JA, Schoepp DD. Dopamine and 5-HT turnover are increased by the mGlu2/3 receptor agonist LY379268 in rat medial prefrontal cortex, nucleus accumbens and striatum. Brain Res 2000; 887: 378-384.
31. Swanson LW. Brain maps. Structure of the Rat Brain, 2nd revised edn. Elsevier: Amsterdam, 1998.
32. Braff DL, Geyer MA. Sensorimotor gating and schizophrenia: human and animal model studies. Arch Gen Psychiatry 1990; 47: 181-188.
33. File SE. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Meth 1980; 2: 219-238.
34. Salmi P, Samuelsson J, Ahlenius S. A new computer-assisted two-way avoidance conditioning equipment for rats: behavioral and pharmacological validation. J Pharmacol Toxicol Meth 1994; 32: 155-159.
35. Kastin AJ, Pan W, Maness LM, Banks WA. Peptides crossing the blood-brain barrier: some unusual observations. Brain Res 1999; 848: 96-100.
36. Sams-Dodd F. Effects of continuous D-amphetamine and phencyclidine administration on social behaviour, stereotyped behaviour, and locomotor activity in rats. Neuropsychopharmacology 1998; 19: 18-25.
37. Thiel CM, Muller CP, Huston JP, Schwarting RK. High versus low reactivity to a novel environment: behavioural, pharmacological and neurochemical assessments. Neuroscience 1999; 93: 243-251.
38. Ison JR, MaAdam DW, Hammond GR. Latency and amplitude changes in the acoustic startle reflex of the rat produced by variation in auditory prestimulation. Physiol Behav 1973; 10: 1035-1039.
39. Grillon C, Ameli R, Charney DS, Krystal J, Braff D. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol Psychiatry 1992; 32: 939-943.
40. Swerdlow NR, Benbow CH, Zisook S, Geyer MA, Braff DL. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry 1993; 33: 298-301.
41. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatry 1995; 58:192-200.
42. Castellanos FX, Fine EJ, Kaysen D, Marsh WL, Rapoport JL, Hallett M. Sensorimotor gating in boys with Tourette's syndrome and ADHD: preliminary results. Biol Psychiatry 1996; 39: 33-41.
43. Compton DR, Johnson KM. Effects of acute and chronic clozapine and haloperidol on in vitro release of acetylcholine and dopamine from striatum and nucleus accumbens. J Pharmacol Exp Ther 1989; 248: 521-530.
44. Burrows RC, Levitt P, Shors TJ. Postnatal decrease in transforming growth factor alpha is associated with enlarged ventricles, deficient amygdaloid vasculature and performance deficits. Neuroscience 2000; 96: 825-836.
45. Kornblum HI, Hussain RJ, Bronstein JM, Gall CM, Lee DC, Seroogy KB. Prenatal ontogeny of the epidermal growth factor receptor and its ligand, transforming growth factor alpha, in the rat brain. J Comp Neurol 1997; 380: 243-261.
46. Nakagawa T, Sasahara M, Hayase Y, Haneda M, Yasuda H, Kikkawa R et al. Neuronal and glial expression of heparin-binding EGF-like growth factor in central nervous system of prenatal and early-postnatal rat. Dev Brain Res 1998; 108: 263-272.
47. Kornblum HI, Gall CM, Seroogy KB, Lanterborn JC. A subpopulation of striatal gabaergic neurons expresses the epidermal growth factor receptor. Neuroscience. 1995; 69: 1025-1029.
48. Misumi Y, Kawano H. The expressions of epidermal growth factor receptor mRNA and protein gene product 9.5 in developing rat brain. Dev Brain Res 1998; 107: 1-9.
49. Imamura K, Kasamatsu T. Ocular dominance plasticity restored by NA infusion to aplastic visual cortex of anesthetized and paralyzed kittens. Exp Brain Res 1991; 87: 309-318.
50. Plessinger MA. Prenatal exposure to amphetamines. Risks and adverse outcomes in pregnancy. Obstet Gynecol Clin North Am 1998; 25: 119-138.
51. Galdzicki Z, Siarey R, Pearce R, Stoll J, Rapoport SI. On the cause of mental retardation in Down syndrome: extrapolation from full and segmental trisomy 16 mouse models. Brain Res Rev 2001; 35: 115-145.
52. Kramer A, Yang FC, Snodgrass P, Li X, Scammell TE, Davis FC, Weitz CJ. Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science 2001; 294: 2511-2515.
53. Ojeda SR, Ma YJ, Rage F. The transforming growth factor alpha gene family is involved in the neuroendocrine control of mammalian puberty. Mol Psychiatry 1997; 2: 355-358.
54. Ma YJ, Berg-von der Emde K, Rage F, Wetsel WC, Ojeda SR. Hypothalamic astrocytes respond to transforming growth factor-alpha with the secretion of neuroactive substances that stimulate the release of luteinizing hormone-releasing hormone. Endocrinology 1997; 138: 19-25.
55. Swerdlow NR, Braff DL, Geyer MA. GABAergic projection from nucleus accumbens to ventral pallidum mediates dopamine-induced sensorimotor gating deficits of acoustic startle in rats. Brain Res 1990; 532: 146-150.
56. Dekeyne A, Brocco M, Adhumeau A, Gobert A, Millan MJ. The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents. Psychopharmacol (Berl) 2000; 152: 55-66.
57. Kalivas PW, Duffy P. Effects of daily cocaine and morphine treatment on somatodendritic and terminal field dopamine release. J Neurochem 1988; 50: 1498-1504.
58. Elverfors A, Nissbrandt H. Effects of d-amphetamine on dopaminergic neurotransmission; a comparison between the substantia nigra and the striatum. Neuropharmacology 1992; 31: 661-670.
59. Borella A, Bindra M, Whitaker-Azmitia PM. Role of the 5-HT1A receptor in development of the neonatal rat brain: preliminary behavioral studies. Neuropharmacology 1997; 36: 445-450.